SEARCH

SEARCH BY CITATION

References

  • 1
    Serratosa JM, Villanueva V, Kerling F, Kasper B. Safety and tolerability of perampanel: a review of clinical trial data. Acta Neurol Scand 2013;127 (Suppl 197): 3035
  • 2
    Krauss GL, Bar M, Biton V et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand 2012;125:815.
  • 3
    Fuseau E, Templeton D, Hussein Z. Population pharmacokinetics and pharmacodynamics of perampanel in patients with refractory partial seizures. Epilepsy Curr 2011;11 (Suppl 1): abs 1.264.
  • 4
    French JA, Krauss GL, Biton V et al. Adjunctive perampanel for refractory partial-onset seizures: randomized Phase III study 304. Neurology 2012;79:58996.
  • 5
    French JA, Krauss GL, Steinhoff BJ et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global Phase III study 305. Epilepsia 2013;54:11725.
  • 6
    Krauss GL, Serratosa JM, Villanueva V et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012;78:140815.
  • 7
    Gazzola DM, Balcer LJ, French JA. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia 2007;48:13037.
  • 8
    Kwan P, Brodie M, Squillacote D, Yang H, Zhu J, Laurenza A. Adjunctive perampanel is effective against partial seizures, irrespective of concomitant antiepileptic drugs (AEDs): a pooled analysis of three Phase III trials. Abstract presented at the 66th American Epilepsy Society Annual Meeting, San Diego, CA, USA, 30 November-4 December, 2012; 1.239.
  • 9
    Ben-Menachem E, Perucca E, Squillacote D, Yang H, Zhu J, Laurenza A. Perampanel improves responder rates, irrespective of concomitant antiepileptic drugs (AEDs), and increases seizure freedom: a pooled analysis of three Phase III trials. Abstract presented at the 66th American Epilepsy Society Annual Meeting, San Diego, CA, USA, 30 November–4 December, 2012; 1.234.
  • 10
    Hussein Z, Ferry J, Krauss GL, Squillacote D, Laurenza A. Demographic factors and concomitant antiepileptic drugs have no effects on the pharmacodynamics of perampanel. Poster P06.127 presented at the 64th American Academy of Neurology Annual Meeting, New Orleans, LA, USA, April 21–28, 2012.
  • 11
    Kramer L, Perucca E, Ben-Menachem E et al. Perampanel, a selective, non-competitive AMPA receptor antagonist, as adjunctive therapy in patients with refractory partial-onset seizures: a dose-response analysis from Phase III studies. Poster P06.117 presented at the 64th American Academy of Neurology Annual Meeting, New Orleans, LA, USA, April 21–28, 2012.
  • 12
    Laurenza A, Ferry J, Hussein Z. Population pharmacokinetics and pharmacodynamics of perampanel: a pooled analysis from three phase III trials. Epilepsy Curr 2012;12 (Suppl 1): abs 2.231.
  • 13
    Rektor I, Krauss GL, Bar M et al. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand 2012;126:2639.
  • 14
    Krauss GL, Perucca E, Ben-Menachem E et al. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, open-label extension study 307. Epilepsia 2013;54:12634.